- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02249442
Study to Determine the Pharmacokinetics on TPV/r in Subjects With Mild and Moderate Hepatic Insufficiency
An Open-label Study to Determine the Pharmacokinetics of Single-dose and/or Steady-state TPV/r 500/200 mg in Subjects With Mild and Moderate Hepatic Insufficiency
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Signed informed consent prior to trial participation.
Male and female subjects with:
- Diagnostically established hepatic disease with mild hepatic insufficiency (defined as maximum ever Child-Pugh score ≤6) or
- Diagnostically established hepatic disease with moderate hepatic insufficiency (defined as maximum ever Child-Pugh score ≤9) for less than 5 years. Current Child-Pugh score must be less than 9 or
- Subjects matched by gender, race, age (±3 years), and weight (±3 kg) and cigarette smoking (matched where possible by +/- .25 pack years) to subjects with mild or moderate hepatic impairment already enrolled in the study.
- Body Mass Index (BMI) between 18 and 29 kg/m2
- Subjects ≥18 and ≤75 years old.
- Ability to swallow multiple large capsules without difficulty.
Laboratory values that indicate adequate baseline organ function are required at the time of screening. All subjects (including healthy controls) should have all laboratory values less than or equal to Grade 1, based on the AIDS Clinical Trial Group (ACTG) Grading Scale.The following exceptions will be made only for subjects with mild or moderate hepatic insufficiency:
- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <5 x upper limit normal (ULN) (≤ Grade 2)
- Alkaline Phosphatase <2 x ULN
- Hemoglobin >10.0 g / dL
- Platelets >75,000 / μl
- Willingness to abstain from alcohol starting 2 days prior to administration of study drug up to the end of the study.
- Willingness to abstain from the following 72 hours prior to pharmacokinetic (PK) sampling: Garlic supplements, methylxanthine containing drinks (coffee, tea, cola, energy drinks, chocolate, etc.).
- Willingness to abstain from over the counter herbal medications for the duration of the study.
- Acceptable medical history, physical examination and chest X-ray (at investigator's discretion) are required prior to entering the treatment phase of the study.
- Willingness to abstain from the following starting 14 days prior to administration of study drug up until the end of the study: Grapefruit or grapefruit juice; Red wine; Seville oranges (marmalade); St. John's Wort or Milk Thistle.
- Willingness to abstain from vigorous physical exercise during intense PK study days (Days 1 and 7).
- Reasonable probability for completion of the study, including dosing requirements of TPV/r and risk for hepatic decompensation among subjects with mild and moderate hepatic insufficiency.
Exclusion Criteria:
Female subjects who are of reproductive potential who:
- Have positive serum β-hCG (Human chorionic gonadotropin test for pregnancy) at Visit 1 or on Day 0.
- Have not been using a barrier contraceptive method for at least 3 months prior to Day 0 (Visit 2).
- Are not willing to use a reliable method of at least barrier contraception, during the trial and 60 days after completion/termination.
- Are breast-feeding.
- Participation in another trial with an investigational medicine within 60 days prior to Day 0 (Visit 2).
- Use of any medication listed in the protocol within 30 days prior to Day 0 (Visit 2).
- Use of any pharmacological contraceptive (including oral or patch) for one month prior to study initiation and for the duration of the study. Use of implantable or injectable contraceptive agents is excluded for at least six months prior to study start.
- Use of hormone replacement therapy with estrogen-based preparations for at least 1 month prior to study initiation and for the duration of the study.
- Administration of antimicrobial agents within 10 days prior to Day 0 (Visit 2) or during the trial.
- Subjects with a history of spontaneous bacterial peritonitis, advanced hepatic cirrhosis (including Child's-Pugh score >8), active esophageal variceal disease, or asterixis.
- Subjects with active or untreated hepatocellular carcinoma or who test positive for serum alpha fetoprotein (>10mg/dL).
- Subjects with active coagulopathy.
- Have serological evidence of exposure to, or infection with, HIV.
- Recent history of alcohol or substance abuse (within 6 months of study period).
- Blood or plasma donations within 30 days prior to Day 0 (Visit 2).
- Subjects with a seated systolic blood pressure either <100 mm Hg or >150 mm Hg; resting heart rate either <50 beats/min or >90 beats/min. For subjects with a resting heart rate below 50, or above 90, the investigator could discuss exclusion with the medical monitor on a case-by-case basis.
- Subjects with a history of any illness or allergy that, in the opinion of the investigator, might confound the results of the study or pose additional risk in administering TPV and ritonavir (RTV).
- Subjects who have had an acute illness within 2 weeks prior to Day 0 (Visit 2).
- Current use of any medications to control symptoms of hepatic disease within 30 days prior to Day 0, (Visit 2) or for the duration of the trial.
- Known hypersensitivity to TPV, Ritonavir or the sulphonamide class of drugs.
- Inability to adhere to the requirements of the protocol.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Scheme A, mild hepatic subjects
multi-dose
|
|
Experimental: Scheme B, moderate hepatic subjects
single dose
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
AUC0-∞ (area under the concentration time curve of drug in plasma over the time interval from 0 extrapolated to infinity)
Time Frame: Up to day 12 after first drug administration
|
Up to day 12 after first drug administration
|
AUC0-12h (area under the concentration time curve of drug in plasma over the time interval from 0 to 12h)
Time Frame: Up to 12 hours after drug administration
|
Up to 12 hours after drug administration
|
Cmax (maximum concentration of drug in plasma)
Time Frame: Up to day 12 after first drug administration
|
Up to day 12 after first drug administration
|
Cp12h (drug concentration in plasma at 12 hours after administration) for the mild hepatic subjects
Time Frame: Up to 12 hours (h) after drug administration
|
Up to 12 hours (h) after drug administration
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
time from dosing to the maximum concentration (tmax)
Time Frame: Up to day 12 after first drug administration
|
Up to day 12 after first drug administration
|
|
elimination half-life (t1/2)
Time Frame: Up to day 12 after first drug administration
|
Up to day 12 after first drug administration
|
|
oral clearance (CL/F)
Time Frame: Up to day 12 after first drug administration
|
Up to day 12 after first drug administration
|
|
volume of distribution (Vz/F)
Time Frame: Up to day 12 after first drug administration
|
Up to day 12 after first drug administration
|
|
Relationship between pharmacokinetic parameters and baseline covariates
Time Frame: Up to day 12 after first drug administration
|
Covariates = age, weight, race, cigarette smoking and hepatic impairment
|
Up to day 12 after first drug administration
|
Relationship between pharmacokinetic parameters and baseline covariates
Time Frame: Up to day 12 after first drug administration
|
Covariates = age, weight, race, cigarette smoking and the child-Pugh score as linear and quadratic terms
|
Up to day 12 after first drug administration
|
Number of patients with abnormal changes in clinical laboratory parameters
Time Frame: Up to day 12 after first drug administration
|
Up to day 12 after first drug administration
|
|
Number of patients with adverse events
Time Frame: Up to day 12 after first drug administration
|
Up to day 12 after first drug administration
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Liver Diseases
- Liver Failure
- Hepatic Insufficiency
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Anti-HIV Agents
- Anti-Retroviral Agents
- Protease Inhibitors
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 Enzyme Inhibitors
- HIV Protease Inhibitors
- Viral Protease Inhibitors
- Ritonavir
- Tipranavir
Other Study ID Numbers
- 1182.32
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatic Insufficiency
-
PfizerCompletedHealthy, Hepatic InsufficiencyUnited States
-
BeiGeneCompletedHepatic Insufficiency & Healthy SubjectsUnited States
-
BayerCompletedHepatic Insufficiency, Renal InsufficiencyGermany, Romania
-
Cardiox CorporationTerminatedHepatic Failure
-
Novartis PharmaceuticalsCompletedHepatic FailureUnited States
-
Centre Hospitalier Universitaire de NiceCompleted
-
Biotie Therapies Inc.Acorda TherapeuticsTerminatedHepatic ImpairmentUnited States
-
PfizerMedivation, Inc.Completed
-
Assistance Publique - Hôpitaux de ParisUnknownFulminating Hepatic FailureFrance
-
National Taiwan University HospitalUnknownLiver Failure | Critical CareTaiwan
Clinical Trials on Tipranavir (TPV)
-
Boehringer IngelheimTerminated
-
Medtronic Heart ValvesCompletedTetralogy of Fallot | Congenital Heart DiseaseUnited States, Canada
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted
-
Taewoong Medical Co., Ltd.AvaniaActive, not recruitingHeart Diseases | Tetralogy of Fallot | Pulmonary Valve Stenosis | Pulmonary Valve RegurgitationGermany, Spain, Korea, Republic of, Italy, Netherlands, Turkey
-
Seoul National University HospitalCompletedCardiovascular Abnormalities | Pulmonary Valve Insufficiency | Pulmonary Valve Stenosis | Congenital Heart DefectsKorea, Republic of
-
Boehringer IngelheimCompleted